Vasopressin Enters the ICU as a Ready-to-Use Pressor for Refractory Vasodilatory Shock
Vasopressin in Sodium Chloride Injection is labeled to raise blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. In practical bedside terms, the drug is positioned as an adjunct when the circulation has already been volume-resuscitated and adrenergic support is not enough to restore vascular tone. The formulation is supplied as a ready-to-use intravenous infusion, which removes a compounding step that can slow treatment during a hemodynamic crisis.
The label identifies two clinical settings in which the infusion is used differently: post-cardiotomy shock and septic shock. Post-cardiotomy shock calls for a starting dose of 0.03 units/minute, while septic shock begins at 0.01 units/minute. In both situations, titration proceeds in 0.005-unit/minute increments every 10 to 15 minutes until the target blood pressure is reached. The product is not diluted before administration, and the label directs clinicians to titrate to the lowest dose compatible with a clinically acceptable response.
In shock states, endogenous vasopressin physiology often becomes relevant again. When arterial vasodilation dominates the bedside picture, replacing this hormone can tighten vascular smooth muscle and augment systemic vascular resistance without relying solely on catecholamine receptor stimulation. That mechanism explains why the drug sits alongside norepinephrine-class therapy rather than replacing it outright. The label also cautions that the pressor effect of catecholamines and vasopressin is expected to be additive, which fits the real-world approach of layered vasopressor support in the intensive care unit.
Dose Escalation, Tapering, and the Limits of High-Intensity Pressor Therapy
The dosing language is intentionally conservative. For both labeled indications, there are limited data above 0.1 units/minute in post-cardiotomy shock and above 0.07 units/minute in septic shock, and adverse reactions are expected to increase as doses rise. After target blood pressure has been maintained for 8 hours without catecholamines, the infusion should be tapered by 0.005 units/minute each hour as tolerated to maintain the blood pressure goal. In other words, this is not a drug to leave running indefinitely at an aggressive dose once the hemodynamic window has narrowed.
A single sentence in the warnings section carries outsized clinical weight: the drug can worsen cardiac function. In a patient whose shock state already reflects myocardial strain, that risk matters because vasoconstriction can improve perfusion pressure while simultaneously increasing afterload. The heart may not tolerate that tradeoff. Bradycardia, tachyarrhythmias, decreased cardiac output, and ischemic events are all listed among the most common adverse reactions, and the ischemia signal extends to coronary, mesenteric, skin, and digital beds.
Hyponatremia appears on the adverse-reaction list as well, reflecting the antidiuretic biology of vasopressin. The same receptor activity that helps conserve water can complicate electrolyte management, especially when patients are already receiving large-volume resuscitation and multiple vasoactive agents. Reversible diabetes insipidus is also named as a warning, a reminder that the endocrine effects of this hormone are not one-directional and can shift in both directions depending on the clinical context and interacting medications.
Contraindications, Interactions, and Population-Specific Caution
The only listed contraindication is known allergy or hypersensitivity to 8-L-arginine vasopressin. Beyond that, the label is dense with interaction warnings that matter at the bedside. Ganglionic blockers and drugs associated with SIADH may increase the pressor response, while drugs associated with diabetes insipidus may decrease it. Indomethacin may prolong the effects of vasopressin. These interactions are pharmacologically coherent: anything that changes water handling or autonomic tone can alter both the vascular and antidiuretic consequences of the infusion.
Pregnancy adds a separate concern. The label states that vasopressin may induce tonic uterine contractions, which is a meaningful safety issue if the drug is used in a pregnant patient with shock. Pediatric safety and effectiveness have not been established. In older adults, no safety issues have been identified, although that wording does not erase the need for careful monitoring in a population that often carries structural heart disease, chronic kidney disease, and competing causes of hypotension.
The commercial presentation is straightforward: 100-mL single-dose ready-to-use containers containing either 20 units of vasopressin at 0.2 units/mL or 40 units at 0.4 units/mL in 0.9% sodium chloride. The solution is described as clear and practically colorless. Before infusion, clinicians are instructed to inspect visually for particulate matter and discoloration, and any unused portion should be discarded. No additive should be introduced into the container.
The label revision is dated February 2024, with an updated labeling entry posted in February 2025. For ICU teams, the practical consequence is not a new physiologic concept but a more standardized delivery format for an old and powerful pressor. The safety margins remain narrow, the hemodynamic benefit depends on close titration, and the major risks are not subtle: cardiac suppression, ischemia, arrhythmia, and electrolyte disturbance can emerge while the blood pressure trace looks better.